US20130203109A1 - Methods and Compositions for Hematoxylin and Eosin Staining - Google Patents

Methods and Compositions for Hematoxylin and Eosin Staining Download PDF

Info

Publication number
US20130203109A1
US20130203109A1 US13/750,686 US201313750686A US2013203109A1 US 20130203109 A1 US20130203109 A1 US 20130203109A1 US 201313750686 A US201313750686 A US 201313750686A US 2013203109 A1 US2013203109 A1 US 2013203109A1
Authority
US
United States
Prior art keywords
solution
staining
buffered solution
hematoxylin
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13/750,686
Other languages
English (en)
Inventor
Stanley E. Hansen
Russell Myers
Ronald Paul
Audra Rasmussen
Kate Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leica Biosystems Richmond Inc
Original Assignee
Leica Biosystems Richmond Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leica Biosystems Richmond Inc filed Critical Leica Biosystems Richmond Inc
Priority to US13/750,686 priority Critical patent/US20130203109A1/en
Publication of US20130203109A1 publication Critical patent/US20130203109A1/en
Priority to US14/268,274 priority patent/US9423322B2/en
Priority to US15/216,910 priority patent/US10234365B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6827—Total protein determination, e.g. albumin in urine
    • G01N33/6839—Total protein determination, e.g. albumin in urine involving dyes, e.g. Coomassie blue, bromcresol green
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/30—Staining; Impregnating ; Fixation; Dehydration; Multistep processes for preparing samples of tissue, cell or nucleic acid material and the like for analysis
    • G01N2001/302—Stain compositions

Definitions

  • H and E staining technique is the most commonly used histological technique for the visualization of pathology in tissue specimens.
  • a typical H and E staining system is composed of solutions comprising aluminum based hematoxylin, eosin, a differentiating solution, and a bluing agent.
  • Hematoxylin is a natural dye that when complexed with aluminum ions produces a positively charged molecule that binds to deoxyribonucleic acid to produce a purple coloration of cell nuclei.
  • Differentiation solutions typically are lightly acidic solutions that sharpen the contrast of the stained slide by removing excessive background staining from the tissue and slide.
  • Bluing agents are solutions of a basic pH that when applied to stained specimens modify the structure of the bound hematoxylin to produce a vibrant blue/purple coloration.
  • Eosin is a negatively charged dye that binds to positively charged proteins within the cytoplasm and connective tissue to produce a pink/orange coloration that contrasts with the blue/purple coloration of the nuclei.
  • H and E staining is most commonly performed in a “batch” format wherein automated stainers typically contain a series of staining reagent containers and utilize a robotic arm for the sequential movement of slides/racks from one container to another.
  • a rack or holder is capable of carrying 20 to 30 slides although some staining instruments incorporate racks that hold fewer or greater numbers of slides per rack and in the case of at least one stainer, multiple racks may be places into a staining vessel simultaneously.
  • Software controlling an automated stainer allows the operator to program the duration of each of the steps as well as the sequence of the steps. While the batch format of staining is simple, economical, and relatively rapid, there are drawbacks with the technique.
  • Carry-over occurs due to the adherence of staining reagents or water to the slides, samples, the slide rack, etc. Carry-over is undesirable because it may affect the functionality of the downstream staining reagents in several ways. Carry-over dilutes the concentration of the dyes or functional reagents within a solution. Carry-over and dilution can also affect the functionality of the staining reagent by changing the characteristics of the solvent and thus affecting such parameters such as pH and ionic strength of the solvent. Finally, carry-over may introduce contaminants to the staining reagent.
  • carry-over negatively impacts the performance, functionality, stability, predictability, and capacity of the staining system. Although a single instance of carry-over may result in such negative impacts, the negative impacts of carry-over are especially problematic over the course of multiple staining runs as the negative impacts build or are amplified as the result of the cumulative effects of repeated carry-over.
  • Certain embodiments of the present invention provide for solutions of a defined composition useful in a staining protocol when used at certain points of the staining protocol.
  • the formulations of these solutions are such that carry-over of the solutions will not negatively impact, or preferably, will stabilize or favorably modify staining reagent solutions coming in contact with solutions defined herein.
  • solutions are buffered to maintain a specific pH that when carried-over—such as carried-over into hematoxylin—will not significantly influence the pH of the next staining reagent.
  • Certain embodiments of the invention are drawn to methods of reducing the undesirable impact of solution carry-over in an H and E staining system.
  • defined solutions are used at various steps of the staining protocol, such as before certain staining reagent steps, to reduce the undesirable impact of carry-over.
  • certain embodiments of the invention are drawn to a pH buffered solution comprising an organic acid and a polyhydroxy alcohol.
  • the pH buffered solution has a pH buffering range that comprises from about pH 2.0 to about pH 5.0.
  • the pH buffered solution has a pH buffering range of from about pH 1.0 to about pH 7.0, or from about pH 1.0 to about pH 6.0, or from about pH 1.0 to about pH 5.0., or from about pH 2.0 to about pH 7.0, or from about pH 2.0 to about pH 6.0.
  • such pH buffered solution has a pH buffering range of from about pH 2.0 to about pH 5.0.
  • the pH buffered solution may comprise from about 5% to about 30% (v/v) of a polyhydroxy alcohol selected from the group consisting of ethylene glycol, propylene glycol, glycerin, and polyethylene glycol and may comprise from 10 mM to about 100 mM of an organic acid selected from the group consisting of malic acid, citric acid, maleic acid, acetic acid, and tartaric acid.
  • the pH buffered solution may also comprise an antimicrobial agent that is effective over at least a pH range of from about pH 2.0 to about pH 5.0.
  • Certain embodiments of the invention are drawn to a solution with a pH of from about pH 2.0 to about pH 5.0 comprising aluminum salts and from about 5% to about 30% (v/v) of a polyhydroxy alcohol selected from the group consisting of ethylene glycol, propylene glycol, glycerin, and polyethylene glycol.
  • Certain embodiments of the invention are also drawn to a method of staining a tissue specimen with hematoxylin, the method comprising the steps of (i) contacting the specimen to a defined solution of the invention and (ii) transferring the specimen to a hematoxylin staining solution. Additionally, the method may comprise the steps of rinsing the specimen with water and then contacting the specimen with the buffered solution.
  • kits for performing hematoxylin and eosin staining comprising a defined solution of the invention and at least one hematoxylin and eosin staining reagent selected from the group consisting of a hematoxylin solution, an eosin solution, a differentiating solution, and a bluing agent solution.
  • FIG. 1 shows the steps of a typical hematoxylin and eosin staining protocol.
  • FIG. 2 shows changes in the pH of a hematoxylin solution during the sequential staining of 2,500 slides with specimens. Staining of multiple slides results in an increase in the pH of the hematoxylin solution (solid line). Placement of a buffered solution of defined composition prior to the hematoxylin prevents an increase in pH of the hematoxylin (dashed line).
  • FIG. 3 shows changes in the quality of hematoxylin staining of specimens following the sequential staining of 2,500 slides. Increased cytoplasmic background staining and loss of detail is present in the 2,500 th slide as compared to the first slide.
  • FIG. 4 shows consistent hematoxylin staining observed in the first and 2,500 th sequentially stained specimens. Slides were stained with a protocol using a buffered solution of defined composition of the invention between the tap water rinse and the hematoxylin solution.
  • a “staining reagent” refers to any reagent used in a histological staining protocol. Where it is necessary to understand the invention by specifically referring to “a reagent that is a stain” versus “a reagent in the staining process that is not a stain,” such a distinction is explicitly made.
  • a “working strength” or “ready-to-use” solution is a solution wherein the components in the solution are at the desired concentration for use in the methods of the present invention. “Ready-to-use” may also imply that the solution does not require any additional manipulation on the part of the end user such as filtration, skimming, and/or mixing.
  • xylene substitutes which are in widespread use include two classes: terpenes and aliphatic solvents.
  • terpenes include limonene and turpentine.
  • tap water is most economical to use as a rinse step in high capacity H and E staining protocols.
  • water refers to tap water, but also covers distilled or deionized water or aqueous solutions used to treat or rinse specimens in an H and E staining system.
  • H and E Hematoxylin and Eosin
  • H and E staining is a widely used staining method for histological purposes.
  • One of skill in the art will recognize that many variations and protocols for H and E staining have been developed and where the present invention is applicable, the present invention is not limited to any specific variation, protocol, system, or the like.
  • a typical H and E staining system may be defined as composed of four core staining reagents: hematoxylin, differentiator, bluing reagent, and eosin, as well as the necessary rinses and solvents utilized for deparaffinization, rehydration, dehydration, and clearing.
  • a typical, representative H and E staining protocol comprises the steps of (i) deparaffinization (using xylenes or xylene substitutes), (ii) rehydration (using alcohols), (iii) water rinse, (iv) hematoxylin, (v) water rinse, (vi) differentiator, (vii) water rinse, (viii) bluing, (ix) water rinse, (x) alcohol, (xi) eosin, (xii) dehydration (using alcohols), and (xiii) clearing (using xylenes or xylene substitutes) (Sheenan, D. C. and Hrapchak, B. B.: Theory and Practice of Histotechnology 2 nd ed.
  • a step of using a defined solution immediately precedes a step in the H and E staining protocol.
  • the composition of the solution is dictated by the staining reagent that the solution is designed to protect from carry-over.
  • a step of using a defined solution of the invention immediately precedes a core staining reagent step.
  • a step of using a defined solution immediately precedes the hematoxylin step. In certain embodiments of the invention, a step of using a defined solution immediately precedes the differentiator step. In certain embodiments of the invention, a step of using a defined solution immediately precedes the bluing reagent step. In certain embodiments of the invention, a step of using a defined solution immediately precedes the eosin step.
  • a solution with a defined composition is placed between a water rinse step and the hematoxylin solution.
  • the rinse water is tap water.
  • the defined solution mitigates several adverse effects of the water on the hematoxylin solution.
  • the volume of components for example, ions, chlorine, etc.
  • the addition of a buffer to the solution reduces the capacity of the water to increase the pH of the hematoxylin ( FIG. 2 ). This is advantageous because an increase in the pH of the hematoxylin results in background staining of tissues and loss of staining detail ( FIGS. 3 and 4 ).
  • the defined solution may be formulated to enhance the stability of a hematoxylin exposed to carry-over of the solution.
  • the addition of a polyhydroxy alcohol to the solution to be carried over to the hematoxylin can reduce the likelihood of precipitation of the hematoxylin and can provide value to the user as filtration of the hematoxylin will not be necessary.
  • a step of “using” a solution means exposing a sample—for example a tissue specimen mounted on a slide—to a solution.
  • a sample may be exposed to a solution, for example, by dunking or immersing it in the solution.
  • a sample may be exposed to a solution, for example, by passing the solution over the sample, such as by passing a solution over a slide holding a sample.
  • a sample may be exposed to a solution, for example, by dropping or spraying the solution onto a sample.
  • One of skill in the art will recognize that there may be various alternative methods of exposing a sample to a solution during the staining process, and that the method and solutions of the present invention are not limited to any particular method of exposing a sample to solution.
  • One aspect of the present invention provides for solutions of defined composition for mitigating the effects of water or staining reagent carry-over in a histological staining protocol.
  • the defined solution is a buffered solution comprising an acid, the buffered solution being capable of buffering from between about pH 2.0 to about pH 5.0.
  • the acid has a pKa of from about 2.0 to about 5.0.
  • the concentration of the acid in the solution is from about 10 mM to about 100 mM.
  • the concentration of the acid in the solution is from about 20 mM to about 100 mM.
  • the concentration of the acid in the solution is from about 10 mM to about 50 mM or from about 20 mM to about 50 mM.
  • the acid is an organic acid.
  • the buffered solution comprises a polyhydroxy alcohol at a concentration of from about 5% to about 30% (v/v).
  • polyhydroxy alcohols include, but are not limited to, ethylene glycol, polyethylene glycol, propylene glycol, and glycerin.
  • the solution comprises both an acid and a polyhydroxy alcohol in the amounts and as defined herein.
  • the buffered solution is a solution comprising 20 mM tartaric acid and 15% (v/v) ethylene glycol and the solution pH is adjusted to a pH of 3.3.
  • pH is adjusted with sodium hydroxide (NaOH).
  • the defined solution is an unbuffered solution with a pH of from about pH 2.0 to about pH 5.0 comprising aluminum salts.
  • aluminum salts include, but are not limited to, aluminum ammonium sulfate [AlNH 4 (SO 4 ) 2 ], aluminum sulfate [Al 2 (SO 4 ) 3 ], and aluminum potassium sulfate AlK(SO 4 ) 2 .
  • the unbuffered aluminum salt solution also comprises a polyhydroxy alcohol as described herein at a concentration of from about 15% to about 30% (v/v).
  • the defined solution is a slightly modified or non-modified formulation of the staining reagent used as the differentiator.
  • the slightly modified or non-modified formulation of the staining reagent used as the differentiator is a solution buffered with any acid, where the acid has a pKa of from about 2.5 to about 4.0 and is capable of buffering between a pH of from about pH 1.5 to about pH 5.0.
  • the acid is an organic acid. Representative examples of useful organic acids include, but are not limited to, malic acid, citric acid, fumaric acid, maleic acid, acetic acid, and tartaric acid.
  • an antimicrobial agent may be added to inhibit microbial growth.
  • the antimicrobial agent is one that is effective over at least a pH range of from about pH 2.0 to about pH 5.0.
  • Representative examples of microbial agents include sodium azide, PROCLIN 300®, PROCLIN 150®, PROCLIN 200®, and PROCLIN 950®.
  • the solution contains from about 0.03% to about 0.04% (v/v) PROCLIN 300® (Sigma Aldrich, St. Louis, Mo.) to inhibit microbial growth. It is to be understood that example product or trade names known to those of ordinary skill in the art are provided for illustrative purposes only and are not meant to be limiting of the broader genus of reagents described.
  • the defined solutions such as the buffered solutions, of the invention will be provided as a working strength or ready-to-use solution for H and E staining protocols.
  • concentrated solutions of two or more components may be prepared wherein a user may add water and/or other components (such as an antimicrobial) to the defined solution to prepare a working strength or ready-to-use solution with the formulations described herein.
  • the present invention is also drawn to concentrated solutions that can be used to prepare the defined solutions of the invention. Given the amounts of components in the defined solutions provided, it is within the skill of one of ordinary skill in the art to determine what the amounts of components in a concentrated solution must be to provide for a working strength or ready-to-use solution. For example, if the concentrate is to be diluted 1:1 with water, then the concentration of an acid, polyhydroxy alcohol, etc., would be twice what the desired final concentration would be.
  • One aspect of the present invention provides for methods of mitigating the effects of water or staining reagent carry-over in a histological staining protocol.
  • such methods utilize a defined solution as a step in the staining process between two staining reagent steps or between a water rinse step and a staining reagent step.
  • the samples may also be immersed in the defined solution.
  • staining protocols where samples are contacted with staining reagents in a manner other than immersion, the samples may be contacted with the defined solution in a likewise manner. It is understood, however, that the manner in which the samples are contacted with the staining reagents does not limit the manner in which the sample may be contacted with the defined solution within the same staining protocol.
  • hematoxylin and differentiator solutions In an H and E staining system, the detrimental effects of carry-over are greatest on the hematoxylin and differentiator solutions, but may affect all stains/reagents in a staining system. Hematoxylin and the differentiator follow water rinses in a typical H and E staining schedule. The performance of these two solutions is highly dependent upon pH and the introduction of water to these solutions results in an increase in pH. One effect of increased pH on these solutions is an increase in the background staining of hematoxylin. In certain embodiments, a sample is contacted with a defined solution immediately before being contacted with a hematoxylin staining solution.
  • the sample is contacted with a defined solution immediately after being rinsed in water and immediately before being contacted with a hematoxylin staining solution.
  • the pH of the hematoxylin solution will increase less than 0.30 pH units when exposed to a buffered solution carried over from prior immersion of the specimen in the buffered solution.
  • the pH of the hematoxylin solution will increase less than 0.20 pH units when exposed to a buffered solution carried over from prior immersion of the specimen in the buffered solution.
  • a sample is contacted with a defined solution immediately before being contacted with a differentiator solution. In certain embodiments, the sample is contacted with a defined solution immediately after being rinsed with water and immediately before being contacted with a differentiator solution.
  • Use of the described methods may allow for up to 2,000 standard specimen slides to be processed under standard H and E staining procedures before new reagents are substituted. In certain embodiments, use of the methods may allow for up to 2,700 slides to be processed before new reagents are substituted. Further, in certain embodiments, use of the methods may allow for up to 3,000 slides to be processed before new reagents are substituted. It is understood by those of skill in the art that the capacity to process a certain number of specimen slides refers to the capacity to process such a number without observing an adverse effect on staining that would be unacceptable for the purpose for which the slides are being stained. It is further contemplated that use of the reagents and methods of the invention used in combination with mechanical methods that reduce, but do not completely eliminate carry-over, will also significantly enhance the number of slides that may be stained using a given set of reagents.
  • Methods of the invention may also include the step of diluting a concentrated solution, such as diluting with water, to a final working strength or ready-to-use defined solution.
  • Methods of the invention may also include the step of adding a component, such as an antimicrobial, to prepare a ready-to-use defined solution. This step would be performed before using the defined solution in an H and E staining protocol.
  • kits for performing H and E staining comprise at least a defined solution that mitigates the effects of solution carry-over.
  • Useful defined solutions are described in detail in this application and include buffered and unbuffered solutions.
  • Representative kits of the invention may also comprise one or more staining reagents or other components used for H and E staining.
  • staining reagents used for H and E staining include hematoxylin solution, eosin solution, a differentiating solution, and a bluing agent solution.
  • other components used for H and E staining include xylenes, xylene substitutes, and alcohols.
  • the kit comprises at least the five reagents: (1) hematoxylin solution, (2) eosin solution, (3) a differentiating solution, (4) a bluing agent solution, and (5) a defined solution that mitigates the effects of solution carry-over.
  • kits for performing H and E staining include using a defined solution that mitigates the effects of carry-over as described in detail in this application.
  • the use of a kit provides numerous benefits. Current H and E staining procedures and reagents are subject to the negative effects of solution carry-over, often necessitating that the solutions be changed at different rates.
  • the inclusion of a defined solution that mitigates the effects of solution carry-over in a kit provides for a predictable lifespan of all the kit reagents that is consistent, such that the kit reagents require changing at the same time.
  • kit reagents may allow for up to 2,000 standard specimen slides to be processed using standard H and E staining procedures before new reagents are substituted. Or use of the kit may allow for up to 2,700 slides to be processed before new reagents are substituted. Or use of the kit may allow for up to 3,000 slides to be processed before new reagents are substituted.
  • FIG. 2 demonstrates the increase in pH of the hematoxylin that occurs as slide racks with slides carry over tap-water to the hematoxylin.
  • the placement of a buffered reagent of defined composition between the tap water and the hematoxylin displaces the tap-water from the slides prior to movement into the hematoxylin solution.
  • the pH of the hematoxylin remains stable.
  • Table 1 shows a standard H and E protocol performed on a LEICA® ST-5010XLTM Automated Stainer.
  • Table 2 shows an H and E protocol using a buffered solution of defined composition places between the tap water rinse step and hematoxylin step (Step 10 in Table 2) on a LEICA® ST-5010XLTM Automated Stainer.
  • Table 3 shows a representative example of a buffered solution of defined composition of the invention, such as for use immediately prior to contacting a specimen slide with hematoxylin solution.
  • the pH is adjusted to 3.33 with 2N NaOH.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US13/750,686 2012-01-26 2013-01-25 Methods and Compositions for Hematoxylin and Eosin Staining Abandoned US20130203109A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/750,686 US20130203109A1 (en) 2012-01-26 2013-01-25 Methods and Compositions for Hematoxylin and Eosin Staining
US14/268,274 US9423322B2 (en) 2012-01-26 2014-05-02 Methods and compositions for hematoxylin and eosin staining
US15/216,910 US10234365B2 (en) 2012-01-26 2016-07-22 Methods and compositions for hematoxylin and eosin staining

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261591181P 2012-01-26 2012-01-26
US13/750,686 US20130203109A1 (en) 2012-01-26 2013-01-25 Methods and Compositions for Hematoxylin and Eosin Staining

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/268,274 Division US9423322B2 (en) 2012-01-26 2014-05-02 Methods and compositions for hematoxylin and eosin staining

Publications (1)

Publication Number Publication Date
US20130203109A1 true US20130203109A1 (en) 2013-08-08

Family

ID=47664460

Family Applications (3)

Application Number Title Priority Date Filing Date
US13/750,686 Abandoned US20130203109A1 (en) 2012-01-26 2013-01-25 Methods and Compositions for Hematoxylin and Eosin Staining
US14/268,274 Active US9423322B2 (en) 2012-01-26 2014-05-02 Methods and compositions for hematoxylin and eosin staining
US15/216,910 Active 2033-04-23 US10234365B2 (en) 2012-01-26 2016-07-22 Methods and compositions for hematoxylin and eosin staining

Family Applications After (2)

Application Number Title Priority Date Filing Date
US14/268,274 Active US9423322B2 (en) 2012-01-26 2014-05-02 Methods and compositions for hematoxylin and eosin staining
US15/216,910 Active 2033-04-23 US10234365B2 (en) 2012-01-26 2016-07-22 Methods and compositions for hematoxylin and eosin staining

Country Status (6)

Country Link
US (3) US20130203109A1 (https=)
EP (2) EP3264095B1 (https=)
JP (3) JP5996675B2 (https=)
CN (2) CN106872715B (https=)
ES (1) ES2827785T3 (https=)
WO (1) WO2013112891A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9423322B2 (en) 2012-01-26 2016-08-23 Leica Biosystems Richmond, Inc. Methods and compositions for hematoxylin and eosin staining
CN105987841A (zh) * 2016-06-30 2016-10-05 赖保思 伊红染色液
JP2018522218A (ja) * 2015-05-22 2018-08-09 ヴェンタナ メディカル システムズ， インク． ヘマトキシリン溶液において生成される沈殿物を除去する又は沈殿物の形成を減少させるための方法及び装置
JP2021508051A (ja) * 2017-12-24 2021-02-25 ヴェンタナ メディカル システムズ， インク． エオシン染色技術
CN114624084A (zh) * 2022-03-18 2022-06-14 深圳市贝安特医疗技术有限公司 一种病理组织切片染色试剂盒的制备、染色方法

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015086485A1 (en) 2013-12-13 2015-06-18 Ventana Medical Systems, Inc. Thermal management in the context of automated histological processing of biological specimens and associated technology
CN105980828B (zh) 2013-12-13 2021-12-17 文塔纳医疗系统公司 用于生物标本组织处理的染色试剂和其它液体及关联技术
CN105651580B (zh) * 2015-12-28 2019-01-29 北京雷根生物技术有限公司 一种苏木素伊红混合染色液
CN106644656B (zh) * 2017-01-06 2019-01-22 杨海玉 苏木素-伊红一步染色法
EP3622266B1 (en) 2017-05-10 2022-08-17 Ventana Medical Systems, Inc. Stabilized two-part hematoxylin solution utilizing ph adjustment, method for staining and kit
CN109813588B (zh) * 2019-02-19 2021-03-02 湖北泰康医疗设备有限公司 一种无需固定的寄生虫染色液
CN110823666A (zh) * 2019-11-27 2020-02-21 李雄 苏木素在制备减少病理常规切片染色后褪色的染色剂中的应用
CN113790945B (zh) * 2021-09-23 2024-02-20 南昌雨露实验器材有限公司 一种改良的苏木精染液及其制备方法
US20250044295A1 (en) * 2021-12-16 2025-02-06 Merck Sharp & Dohme Llc Biomarkers for predicting eligibility for an anti-ilt4 and anti-pd-1 combination therapy

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296090A (en) * 1991-12-03 1994-03-22 New England Medical Center Hospitals, Inc. High resolution track etch autoradiography

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54134694A (en) * 1978-04-12 1979-10-19 Chemo Sero Therapeut Res Inst Method and kit for measuring uric acid
JPS58179499A (ja) 1982-04-13 1983-10-20 Wako Pure Chem Ind Ltd 細菌感受性試験ディスク
JPH0659231B2 (ja) * 1983-02-08 1994-08-10 ヤマサ醤油株式会社 単一クローン抗体
CN88103080A (zh) * 1987-05-25 1988-12-14 奥里尔股份有限公司 成色剂和/或“快速”氧化染色剂与碘化物并用进行角质纤维染色的方法及其中所用染色组合物
JP2702211B2 (ja) * 1989-02-03 1998-01-21 サクラ精機株式会社 ヘマトキシリン染色液
WO1992019952A1 (en) 1991-05-07 1992-11-12 Wescor, Inc. Improved staining method for histology and cytology specimens
JPH05252954A (ja) * 1991-08-06 1993-10-05 Chemo Sero Therapeut Res Inst 新規な組織因子インヒビターをコードする遺伝子断片
US5295998A (en) 1993-02-02 1994-03-22 Liquid Carbonic Industries Corporation Adjusting pH in dyeing processes using CO2
US5432056A (en) * 1993-11-15 1995-07-11 Ventana Medical Systems, Inc. Bisulfite-based tissue fixative
US6735531B2 (en) 1996-10-07 2004-05-11 Lab Vision Corporation Method and apparatus for automatic tissue staining
JP3847559B2 (ja) 1998-02-27 2006-11-22 ベンタナ・メデイカル・システムズ・インコーポレーテツド 独立スライド加熱器を有する自動化分子病理学装置
US7410753B2 (en) 1998-09-03 2008-08-12 Ventana Medical Systems, Inc. Removal of embedding media from biological samples and cell conditioning on automated staining instruments
AU766614B2 (en) * 1998-09-03 2003-10-23 Ventana Medical Systems, Inc. Removal of embedding media from biological samples and cell conditioning on automated staining instruments
US6855552B2 (en) * 1998-09-03 2005-02-15 Ventana Medical Systems Automated immunohistochemical and in situ hybridization assay formulations
JP2000187033A (ja) * 1998-12-21 2000-07-04 Wako Pure Chem Ind Ltd 細胞染色液
US6544798B1 (en) * 1999-02-26 2003-04-08 Ventana Medical Systems, Inc. Removal of embedding media from biological samples and cell conditioning on automated staining instruments
US6348325B1 (en) 1999-10-29 2002-02-19 Cytyc Corporation Cytological stain composition
US6593102B2 (en) 1999-10-29 2003-07-15 Cytyc Corporation Cytological stain composition
US20030100043A1 (en) 2000-03-24 2003-05-29 Biogenex Laboratories, Inc. Device and methods for automated specimen processing
EP1417632A1 (en) 2001-05-29 2004-05-12 Tissueinformatics, Inc. Robust stain detection and quantification for histological specimens based on a physical model for stain absorption
US7468161B2 (en) 2002-04-15 2008-12-23 Ventana Medical Systems, Inc. Automated high volume slide processing system
WO2003089140A1 (en) 2002-04-15 2003-10-30 Ventana Medical Systems, Inc. Automated high volume slide staining system
KR20050083623A (ko) 2002-12-10 2005-08-26 마쯔시다덴기산교 가부시키가이샤 면역반응 측정방법
US7875245B2 (en) 2003-05-14 2011-01-25 Dako Denmark A/S Method and apparatus for automated pre-treatment and processing of biological samples
EP1573298B1 (en) 2002-12-20 2012-08-08 Dako Denmark A/S An automated sample processing apparatus and a method of automated treating of samples and use of such apparatus
US7186522B2 (en) * 2003-03-31 2007-03-06 Cytyc Corporation Papanicolau staining process
ES2381644T3 (es) * 2004-03-24 2012-05-30 Tripath Imaging, Inc. Métodos y composiciones para la detección de enfermedades de cuello uterino
WO2007029437A1 (ja) * 2005-09-06 2007-03-15 Pola Chemical Industries Inc. 角層細胞の染色液及びそれを用いた角層細胞の染色方法
JP2007114076A (ja) * 2005-10-21 2007-05-10 Pola Chem Ind Inc 角層細胞の画像の調整方法
US8189737B2 (en) * 2006-01-26 2012-05-29 The Board Of Regents, The University Of Texas System, A Texas Institution Of Higher Learning Process and apparatus for microCT imaging of ex vivo specimens
US7915432B2 (en) * 2006-12-12 2011-03-29 Cytyc Corporation Method for improving the shelf-life of hematoxylin staining solutions
WO2008112993A1 (en) * 2007-03-15 2008-09-18 Ventana Medical Systems, Inc. Stabilized hematoxylin
KR101244501B1 (ko) * 2007-09-27 2013-03-18 시스멕스 가부시키가이샤 시료 분석용 시약 키트 및 시료 분석 방법
US8158381B2 (en) 2008-03-27 2012-04-17 Richard-Allan Scientific Company Methods for integrated tissue processing and staining
WO2009148885A2 (en) * 2008-05-30 2009-12-10 Ventana Medical Systems, Inc. Hematoxylin staining method to address gradient staining
JP5683501B2 (ja) 2010-02-05 2015-03-11 株式会社ニチレイバイオサイエンス 免疫組織化学染色用前処理液及びその濃縮液
WO2011157678A1 (en) * 2010-06-14 2011-12-22 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
ES2827785T3 (es) 2012-01-26 2021-05-24 Leica Biosystems Richmond Inc Kit para tinción con hematoxilina y eosina

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296090A (en) * 1991-12-03 1994-03-22 New England Medical Center Hospitals, Inc. High resolution track etch autoradiography

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Brittain, H.G. Encyclopedia of Pharmaceutical Technology 3rd Edition, Swarbrick, J., Ed.; Informa Healthcare: New York, 2007; Vol. 1, pages 385-388. *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9423322B2 (en) 2012-01-26 2016-08-23 Leica Biosystems Richmond, Inc. Methods and compositions for hematoxylin and eosin staining
US10234365B2 (en) 2012-01-26 2019-03-19 Leica Biosystems Richmond, Inc. Methods and compositions for hematoxylin and eosin staining
JP2018522218A (ja) * 2015-05-22 2018-08-09 ヴェンタナ メディカル システムズ， インク． ヘマトキシリン溶液において生成される沈殿物を除去する又は沈殿物の形成を減少させるための方法及び装置
US10976223B2 (en) 2015-05-22 2021-04-13 Ventana Medical Systems, Inc. Methods and compositions for removing or reducing formation of precipitates generated in hematoxylin solutions
EP4206645A1 (en) 2015-05-22 2023-07-05 Ventana Medical Systems, Inc. Method and apparatus for removing or reducing formation of precipitates generated in hematoxylin solutions
CN105987841A (zh) * 2016-06-30 2016-10-05 赖保思 伊红染色液
JP2021508051A (ja) * 2017-12-24 2021-02-25 ヴェンタナ メディカル システムズ， インク． エオシン染色技術
JP7449862B2 (ja) 2017-12-24 2024-03-14 ヴェンタナ メディカル システムズ， インク． エオシン染色技術
US11940358B2 (en) 2017-12-24 2024-03-26 Ventana Medical Systems, Inc. Eosin staining techniques
US12332153B2 (en) 2017-12-24 2025-06-17 Ventana Medical Systems, Inc. Eosin staining techniques
CN114624084A (zh) * 2022-03-18 2022-06-14 深圳市贝安特医疗技术有限公司 一种病理组织切片染色试剂盒的制备、染色方法

Also Published As

Publication number Publication date
JP6351670B2 (ja) 2018-07-04
CN104471405A (zh) 2015-03-25
WO2013112891A1 (en) 2013-08-01
CN104471405B (zh) 2017-03-29
US20160327458A1 (en) 2016-11-10
JP2018109637A (ja) 2018-07-12
JP5996675B2 (ja) 2016-09-21
JP2016218081A (ja) 2016-12-22
CN106872715A (zh) 2017-06-20
US9423322B2 (en) 2016-08-23
US20140242634A1 (en) 2014-08-28
US10234365B2 (en) 2019-03-19
ES2827785T3 (es) 2021-05-24
JP2015505062A (ja) 2015-02-16
CN106872715B (zh) 2020-06-16
EP2807490A1 (en) 2014-12-03
EP2807490B1 (en) 2017-09-13
EP3264095A1 (en) 2018-01-03
EP3264095B1 (en) 2020-08-12

Similar Documents

Publication Publication Date Title
US10234365B2 (en) Methods and compositions for hematoxylin and eosin staining
US5318795A (en) Staining methods for histology and cytology specimens
US6451551B1 (en) Releasing embedding media from tissue specimens
US12474240B2 (en) Stabilized two-part hematoxylin solution utilizing pH adjustment
US4404181A (en) Extended-life tissue fixative composition and method of using the same
US20120122151A1 (en) Cytological or histological binding composition and staining methods
JP6688057B2 (ja) グラム染色用後染色試液及びグラム染色方法
US6284543B1 (en) Rapid papanicolaou staining method for cervico-vaginal specimens
AU2001281391A1 (en) Rapid papanicolaou staining method for cervico-vaginal specimens
Dey Routine staining in cytology laboratory
WO2015165850A1 (en) Hematoxylin precipitate cleaning method and system
US2581523A (en) Method of staining slides and staining solutions therefor
US6194165B1 (en) Cell fixative and preparation composition, kit and method
JP5921386B2 (ja) 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
JP2002350431A (ja) 染色標本の脱色方法および装置
US20140248658A1 (en) Cytoplasmic stain composition
JP7178606B2 (ja) 染色された生物組織の脱色法
CN112067409A (zh) 一种改良的小鼠骨髓组织切片h.e染色方法
GB2594354A (en) Mordant and dye composition
Yu 30 Histochemistry Bone and Cartilage

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION